Sep 30, 2015
TSX Exchange Symbol: RVX
CALGARY, Sept. 30, 2015 /CNW/ - Resverlogix Corp. (the "Corporation") (TSX:RVX) today announced that, at its annual and special meeting of shareholders held on September 30, 2015, each of the five nominees proposed as a director and listed in its management information circular dated August 17, 2015 were elected as directors. Proxy voting results for each nominee are set out below:
| Votes For | Votes Withheld | % For | % Withheld | |
| Donald J. McCaffrey | 32,978,486 | 133,690 | 99.60% | 0.40% |
| Peter Johann | 32,990,226 | 121,950 | 99.63% | 0.37% |
| Kelly McNeill | 32,921,276 | 190,900 | 99.42% | 0.58% |
| Kenneth Zuerblis | 33,029,776 | 82,400 | 99.75% | 0.25% |
| Eldon Smith | 32,921,176 | 191,000 | 99.42% | 0.58% |
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Resverlogix's Phase 3 clinical trial BETonMACE in high-risk CVD patients with DM and low HDL is planned to commence in the fall of 2015. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog and via Twitter @Resverlogix_RVX https://twitter.com/resverlogix_rvx.
Company Contacts:
Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252
Email: don@resverlogix.com
Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp.
Phone: 403-254-9252
Email: sarah@resverlogix.com
SOURCE Resverlogix Corp.